Dr. Anna La Salvia is a medical oncologist with a particular
interest in the field of neuroendocrine tumors. She has attained her PhD at
Complutense University of Madrid, Spain, and she has worked at the
Gastrointestinal and Neuroendocrine Tumor Unit, University Hospital 12 de
Octubre, Madrid, Spain (2019–2021) and at the Medical Oncology Unit 2, Clinical
Department and Oncological Research, Regina Elena National Cancer Institute
(IRCCS) (January–October 2022). Currently, she is a Researcher for the National
Center for Drug Research and Evaluation, at the National Institute of Health
(ISS). She has been involved as a sub-investigators in many phase I-II-III
clinical trials, as well as numerous translational research projects. Her
scientific work Is focused on translational research and clinical Oncology, and
it is mainly focused on neuroendocrine tumors.
Dr. Anna La Salvia is a medical oncologist with a particular
interest in the field of neuroendocrine tumors. She has attained her PhD at
Complutense University of Madrid, Spain, and she has worked at the
Gastrointestinal and Neuroendocrine Tumor Unit, University Hospital 12 de
Octubre, Madrid, Spain (2019–2021) and at the Medical Oncology Unit 2, Clinical
Department and Oncological Research, Regina Elena National Cancer Institute
(IRCCS) (January–October 2022). Currently, she is a Researcher for the National
Center for Drug Research and Evaluation, at the National Institute of Health
(ISS). She has been involved as a sub-investigators in many phase I-II-III
clinical trials, as well as numerous translational research projects. Her
scientific work Is focused on translational research and clinical Oncology, and
it is mainly focused on neuroendocrine tumors.